(0.31%) 5 115.59 points
(0.31%) 38 358 points
(0.34%) 15 982 points
(-0.87%) $83.12
(5.82%) $2.04
(0.39%) $2 356.40
(0.48%) $27.67
(4.04%) $959.35
(-0.22%) $0.933
(-0.38%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.74%
@ $9.92
発行日: 15 2月 2024 @ 05:58
リターン: -33.11%
前回のシグナル: 2月 14 - 03:33
前回のシグナル:
リターン: 2.06 %
Live Chart Being Loaded With Signals
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments...
Stats | |
---|---|
本日の出来高 | 66 326.00 |
平均出来高 | 379 898 |
時価総額 | 289.98M |
EPS | $0 ( 2024-03-05 ) |
次の収益日 | ( $-0.100 ) 2024-05-02 |
Last Dividend | $1.000 ( 2010-01-27 ) |
Next Dividend | $0 ( N/A ) |
P/E | -13.01 |
ATR14 | $0.0170 (0.26%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-16 | Zaderej Karen L. | Buy | 84 847 | Common Stock |
2024-03-16 | Zaderej Karen L. | Buy | 12 975 | Common Stock |
2024-03-21 | Zaderej Karen L. | Sell | 3 166 | Common Stock |
2024-03-16 | Zaderej Karen L. | Buy | 12 500 | Common Stock |
2024-03-21 | Zaderej Karen L. | Sell | 3 086 | Common Stock |
INSIDER POWER |
---|
41.83 |
Last 98 transactions |
Buy: 1 200 055 | Sell: 468 598 |
ボリューム 相関
AxoGen Inc 相関
10 最も負の相関 | |
---|---|
SHYF | -0.915 |
RGLD | -0.91 |
UBFO | -0.902 |
MTRX | -0.899 |
ICUI | -0.897 |
TKNO | -0.893 |
IPKW | -0.892 |
STRA | -0.891 |
VRTS | -0.891 |
SGII | -0.889 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
AxoGen Inc 相関 - 通貨/商品
AxoGen Inc 財務諸表
Annual | 2023 |
収益: | $159.01M |
総利益: | $127.87M (80.42 %) |
EPS: | $-0.510 |
FY | 2023 |
収益: | $159.01M |
総利益: | $127.87M (80.42 %) |
EPS: | $-0.510 |
FY | 2022 |
収益: | $138.58M |
総利益: | $114.44M (82.58 %) |
EPS: | $-0.650 |
FY | 2021 |
収益: | $127.36M |
総利益: | $104.43M (81.99 %) |
EPS: | $-0.675 |
Financial Reports:
No articles found.
AxoGen Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0417 | 1992-07-10 |
Last Dividend | $1.000 | 2010-01-27 |
Next Dividend | $0 | N/A |
Payout Date | 2010-02-12 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | $1.102 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.23 | -- |
Div. Sustainability Score | 1.724 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
1992 | $0.0417 | 0.45% |
1993 | $0 | 0.00% |
1994 | $0 | 0.00% |
1995 | $0 | 0.00% |
1996 | $0 | 0.00% |
1997 | $0 | 0.00% |
1998 | $0 | 0.00% |
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0.0600 | 4.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $1.000 | 24.10% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.134 | 1.500 | -2.69 | -4.03 | [0 - 0.5] |
returnOnAssetsTTM | -0.108 | 1.200 | -3.62 | -4.34 | [0 - 0.3] |
returnOnEquityTTM | -0.220 | 1.500 | -3.56 | -5.33 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.89 | 0.800 | 0.540 | 0.432 | [1 - 3] |
quickRatioTTM | 2.04 | 0.800 | 2.69 | 2.15 | [0.8 - 2.5] |
cashRatioTTM | 1.217 | 1.500 | 4.35 | 6.53 | [0.2 - 2] |
debtRatioTTM | 0.245 | -1.500 | 5.92 | -8.88 | [0 - 0.6] |
interestCoverageTTM | -7.45 | 1.000 | -3.87 | -3.87 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.133 | 2.00 | -0.0443 | -0.0885 | [0 - 30] |
freeCashFlowPerShareTTM | -0.479 | 2.00 | -0.240 | -0.479 | [0 - 20] |
debtEquityRatioTTM | 0.503 | -1.500 | 7.99 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.804 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.135 | 1.000 | -4.70 | -4.70 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.119 | 1.000 | -1.771 | -1.771 | [0.2 - 2] |
assetTurnoverTTM | 0.808 | 0.800 | 7.95 | 6.36 | [0.5 - 2] |
Total Score | 1.724 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -13.37 | 1.000 | -1.451 | 0 | [1 - 100] |
returnOnEquityTTM | -0.220 | 2.50 | -2.29 | -5.33 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.479 | 2.00 | -0.160 | -0.479 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.133 | 2.00 | -0.0443 | -0.0885 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.393 | 1.500 | -5.95 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0359 | 1.000 | -3.40 | 0 | [0.1 - 0.5] |
Total Score | -1.990 |
AxoGen Inc
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。